Follow
Benjamin Steyer
Benjamin Steyer
Penn Medicine
Verified email at pennmedicine.upenn.edu
Title
Cited by
Cited by
Year
Electrochemical oxidation of ferrocene: a strong dependence on the concentration of the supporting electrolyte for nonpolar solvents
D Bao, B Millare, W Xia, BG Steyer, AA Gerasimenko, A Ferreira, ...
The Journal of Physical Chemistry A 113 (7), 1259-1267, 2009
1662009
Scarless genome editing of human pluripotent stem cells via transient puromycin selection
B Steyer, Q Bu, E Cory, K Jiang, S Duong, D Sinha, S Steltzer, D Gamm, ...
Stem cell reports 10 (2), 642-654, 2018
732018
Human iPSC modeling reveals mutation-specific responses to gene therapy in a genotypically diverse dominant maculopathy
D Sinha, B Steyer, PK Shahi, KP Mueller, R Valiauga, KL Edwards, ...
The American Journal of Human Genetics 107 (2), 278-292, 2020
412020
Drug-loaded nanoparticles induce gene expression in human pluripotent stem cell derivatives
V Gajbhiye, L Escalante, G Chen, A Laperle, Q Zheng, B Steyer, S Gong, ...
Nanoscale 6 (1), 521-531, 2014
332014
High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells
B Steyer, J Carlson-Stevermer, N Angenent-Mari, A Khalil, T Harkness, ...
Acta biomaterialia 34, 143-158, 2016
312016
High-content analysis of CRISPR-Cas9 gene-edited human embryonic stem cells
J Carlson-Stevermer, M Goedland, B Steyer, A Movaghar, M Lou, ...
Stem cell reports 6 (1), 109-120, 2016
302016
Developing precision medicine using scarless genome editing of human pluripotent stem cells
B Steyer, E Cory, K Saha
Drug Discovery Today: Technologies 28, 3-12, 2018
92018
Inorganic coatings for the enhancement of chemical transfection
WL Murphy, AS Khalil, X Yu, K Saha, JM Carlson-Stevermeyer, BG Steyer
US Patent App. 14/871,327, 2016
52016
Gene therapies differentially rescue disease phenotype in patient-specific hiPSC-RPE models of Best disease
D Sinha, B Steyer, PK Shahi, R Valiauga, KL Edwards, C Bacig, ...
Investigative Ophthalmology & Visual Science 60 (9), 3390-3390, 2019
12019
Developing Gene Therapies for Inherited Retinal Dystrophies Using CRISPR/Cas9 Genomic Editing and Human Pluripotent Stem Cells
A Abdeen, B Steyer, J Carlson-Stevermer, G Chen, Y Wang, R Xie, ...
MOLECULAR THERAPY 27 (4), 255-255, 2019
2019
335. High Content Analysis Platform for Optimization of Lipid Mediated CRISPR-Cas9 Delivery Strategies in Human Cells
B Steyer, J Carlson-Stevermer, N Angenent-Mari, A Khalil, T Harkness, ...
Molecular Therapy 24, S133, 2016
2016
575. High Content Analysis of CRISPR-Cas9 Gene-Edited Human Embryonic Stem Cells
J Carlson-Stevermer, M Goedland, B Steyer, A Movaghar, M Lou, ...
Molecular Therapy 24, S229-S230, 2016
2016
Toward" Rainbow Retinas" that Dynamically Report on Retinal Cell Differentiation in Patient-Specific Stem Cells
B Steyer, E Capowski, D Gamm, K Saha
TISSUE ENGINEERING PART A 21, S195-S195, 2015
2015
The Role of Syndecan‐1 in Arterial Mechanotransduction
AB Baker, V Chitalia, BG Steyer, S Hirji, ER Edelman
The FASEB Journal 24, 480.1-480.1, 2010
2010
STATEMENT OF SIGNIFICANCE
B Steyer, J Carlson-Stevermer, N Angenent-Mari, A Khalil, T Harkness, ...
The system can't perform the operation now. Try again later.
Articles 1–15